Bladder cancer

Ashish M. Kamat, Noah M. Hahn, Jason A. Efstathiou, Seth P. Lerner, Per Uno Malmström, Woonyoung Choi, Charles C. Guo, Yair Lotan, Wassim Kassouf

Research output: Contribution to journalArticle

238 Citations (Scopus)

Abstract

Bladder cancer is a complex disease associated with high morbidity and mortality rates if not treated optimally. Awareness of haematuria as the major presenting symptom is paramount, and early diagnosis with individualised treatment and follow-up is the key to a successful outcome. For non-muscle-invasive bladder cancer, the mainstay of treatment is complete resection of the tumour followed by induction and maintenance immunotherapy with intravesical BCG vaccine or intravesical chemotherapy. For muscle-invasive bladder cancer, multimodal treatment involving radical cystectomy with neoadjuvant chemotherapy offers the best chance for cure. Selected patients with muscle-invasive tumours can be offered bladder-sparing trimodality treatment consisting of transurethral resection with chemoradiation. Advanced disease is best treated with systemic cisplatin-based chemotherapy; immunotherapy is emerging as a viable salvage treatment for patients in whom first-line chemotherapy cannot control the disease. Developments in the past 2 years have shed light on genetic subtypes of bladder cancer that might differ from one another in response to various treatments.

Original languageEnglish (US)
JournalThe Lancet
DOIs
StateAccepted/In press - 2016

Fingerprint

Urinary Bladder Neoplasms
Drug Therapy
Immunotherapy
BCG Vaccine
Salvage Therapy
Muscles
Combined Modality Therapy
Cystectomy
Hematuria
Therapeutics
Cisplatin
Early Diagnosis
Neoplasms
Urinary Bladder
Maintenance
Morbidity
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kamat, A. M., Hahn, N. M., Efstathiou, J. A., Lerner, S. P., Malmström, P. U., Choi, W., ... Kassouf, W. (Accepted/In press). Bladder cancer. The Lancet. https://doi.org/10.1016/S0140-6736(16)30512-8

Bladder cancer. / Kamat, Ashish M.; Hahn, Noah M.; Efstathiou, Jason A.; Lerner, Seth P.; Malmström, Per Uno; Choi, Woonyoung; Guo, Charles C.; Lotan, Yair; Kassouf, Wassim.

In: The Lancet, 2016.

Research output: Contribution to journalArticle

Kamat, AM, Hahn, NM, Efstathiou, JA, Lerner, SP, Malmström, PU, Choi, W, Guo, CC, Lotan, Y & Kassouf, W 2016, 'Bladder cancer', The Lancet. https://doi.org/10.1016/S0140-6736(16)30512-8
Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W et al. Bladder cancer. The Lancet. 2016. https://doi.org/10.1016/S0140-6736(16)30512-8
Kamat, Ashish M. ; Hahn, Noah M. ; Efstathiou, Jason A. ; Lerner, Seth P. ; Malmström, Per Uno ; Choi, Woonyoung ; Guo, Charles C. ; Lotan, Yair ; Kassouf, Wassim. / Bladder cancer. In: The Lancet. 2016.
@article{3d181cd206534e36927ad00cc97d5ef3,
title = "Bladder cancer",
abstract = "Bladder cancer is a complex disease associated with high morbidity and mortality rates if not treated optimally. Awareness of haematuria as the major presenting symptom is paramount, and early diagnosis with individualised treatment and follow-up is the key to a successful outcome. For non-muscle-invasive bladder cancer, the mainstay of treatment is complete resection of the tumour followed by induction and maintenance immunotherapy with intravesical BCG vaccine or intravesical chemotherapy. For muscle-invasive bladder cancer, multimodal treatment involving radical cystectomy with neoadjuvant chemotherapy offers the best chance for cure. Selected patients with muscle-invasive tumours can be offered bladder-sparing trimodality treatment consisting of transurethral resection with chemoradiation. Advanced disease is best treated with systemic cisplatin-based chemotherapy; immunotherapy is emerging as a viable salvage treatment for patients in whom first-line chemotherapy cannot control the disease. Developments in the past 2 years have shed light on genetic subtypes of bladder cancer that might differ from one another in response to various treatments.",
author = "Kamat, {Ashish M.} and Hahn, {Noah M.} and Efstathiou, {Jason A.} and Lerner, {Seth P.} and Malmstr{\"o}m, {Per Uno} and Woonyoung Choi and Guo, {Charles C.} and Yair Lotan and Wassim Kassouf",
year = "2016",
doi = "10.1016/S0140-6736(16)30512-8",
language = "English (US)",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Bladder cancer

AU - Kamat, Ashish M.

AU - Hahn, Noah M.

AU - Efstathiou, Jason A.

AU - Lerner, Seth P.

AU - Malmström, Per Uno

AU - Choi, Woonyoung

AU - Guo, Charles C.

AU - Lotan, Yair

AU - Kassouf, Wassim

PY - 2016

Y1 - 2016

N2 - Bladder cancer is a complex disease associated with high morbidity and mortality rates if not treated optimally. Awareness of haematuria as the major presenting symptom is paramount, and early diagnosis with individualised treatment and follow-up is the key to a successful outcome. For non-muscle-invasive bladder cancer, the mainstay of treatment is complete resection of the tumour followed by induction and maintenance immunotherapy with intravesical BCG vaccine or intravesical chemotherapy. For muscle-invasive bladder cancer, multimodal treatment involving radical cystectomy with neoadjuvant chemotherapy offers the best chance for cure. Selected patients with muscle-invasive tumours can be offered bladder-sparing trimodality treatment consisting of transurethral resection with chemoradiation. Advanced disease is best treated with systemic cisplatin-based chemotherapy; immunotherapy is emerging as a viable salvage treatment for patients in whom first-line chemotherapy cannot control the disease. Developments in the past 2 years have shed light on genetic subtypes of bladder cancer that might differ from one another in response to various treatments.

AB - Bladder cancer is a complex disease associated with high morbidity and mortality rates if not treated optimally. Awareness of haematuria as the major presenting symptom is paramount, and early diagnosis with individualised treatment and follow-up is the key to a successful outcome. For non-muscle-invasive bladder cancer, the mainstay of treatment is complete resection of the tumour followed by induction and maintenance immunotherapy with intravesical BCG vaccine or intravesical chemotherapy. For muscle-invasive bladder cancer, multimodal treatment involving radical cystectomy with neoadjuvant chemotherapy offers the best chance for cure. Selected patients with muscle-invasive tumours can be offered bladder-sparing trimodality treatment consisting of transurethral resection with chemoradiation. Advanced disease is best treated with systemic cisplatin-based chemotherapy; immunotherapy is emerging as a viable salvage treatment for patients in whom first-line chemotherapy cannot control the disease. Developments in the past 2 years have shed light on genetic subtypes of bladder cancer that might differ from one another in response to various treatments.

UR - http://www.scopus.com/inward/record.url?scp=84977580444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977580444&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(16)30512-8

DO - 10.1016/S0140-6736(16)30512-8

M3 - Article

C2 - 27345655

AN - SCOPUS:84977580444

JO - The Lancet

JF - The Lancet

SN - 0140-6736

ER -